Q4 Resuts: Biocon’s Profit Meets Estimates Buoyed By Strong Growth In Biologics Unit
.jpg?downsize=1010:568 "Q4 Resuts: Biocon’s Profit Meets Estimates Buoyed By Strong Growth In Biologics Unit")
Biocon Ltd.'s profit for the March quarter beat estimates due to strong growth in its biologics business.
Biocon's three main businesses—biologics, small molecules and research services—grew at 87 percent, 11 percent and 31 percent, respectively, in the three-month period, according to its exchange filing.
The next wave of biosimilars is going to provide opportunities and growth momentum for the next five years.Kiran Mazumdar Shaw, CMD, Biocon
The Bengaluru-based biopharmaceutical company expects the unit to “deliver handsomely” in the future, its Chairman and Managing Director Kiran Mazumdar Shaw said. Biocon has made huge investments in the biologics business and it would bring huge opportunities for the company, Shaw told BloombergQuint in an interview.
Other Highlights (YoY):
- Revenue rose to Rs 1,529 crore from Rs 1,169 crore.
- Net profit spikes 63.9 percent to Rs 214 crore.
- Ebitda jumped 73 percent to Rs 403 crore.
- Margins improved by 650 basis points to 26.4 percent.
What Went Wrong
Biocon's branded formulations business, however, failed to deliver. The unit's revenue declined 11 percent to Rs 133 crore, according to the filing.
“This (branded formulations) is a very small part of our business,” Shaw said. The business was affected by internal and external factors such as price control measures issued by several industries, including India and the U.A.E., she said.
The slowdown, she said, is not a one-off for the segment as headwinds are likely to continue for the first half of the next fiscal. But Shaw said she's confident that the company's other segments would compensate for the offset in the future.
Watch the full conversation here:
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
